Endothelial cells and astrocytes: A concerto en duo in ischemic pathophysiology

11Citations
Citations of this article
56Readers
Mendeley users who have this article in their library.

Abstract

The neurovascular/gliovascular unit has recently gained increased attention in cerebral ischemic research, especially regarding the cellular and molecular changes that occur in astrocytes and endothelial cells. In this paper we summarize the recent knowledge of these changes in association with edema formation, interactions with the basal lamina, and blood-brain barrier dysfunctions. We also review the involvement of astrocytes and endothelial cells with recombinant tissue plasminogen activator, which is the only FDA-approved thrombolytic drug after stroke. However, it has a narrow therapeutic time window and serious clinical side effects. Lastly, we provide alternative therapeutic targets for future ischemia drug developments such as peroxisome proliferator- activated receptors and inhibitors of the c-Jun N-terminal kinase pathway. Targeting the neurovascular unit to protect the blood-brain barrier instead of a classical neuron-centric approach in the development of neuroprotective drugs may result in improved clinical outcomes after stroke. Copyright © 2012 Vincent Berezowski et al.

Cite

CITATION STYLE

APA

Berezowski, V., Fukuda, A. M., Cecchelli, R., & Badaut, J. (2012). Endothelial cells and astrocytes: A concerto en duo in ischemic pathophysiology. International Journal of Cell Biology. https://doi.org/10.1155/2012/176287

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free